Aarey Drugs & Pharmaceuticals Limited Stock Price Today (NSE: AAREYDRUGS)
Fundamental Score
Aarey Drugs & Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarey Drugs & Pharmaceuticals Limited share price today is ₹99.94, up +1.13% on NSE/BSE as of 16 September 2026. Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹284.37 (Cr). The 52-week high for AAREYDRUGS share price is ₹101.29 and the 52-week low is ₹50.31. At a P/E ratio of 54.61x, AAREYDRUGS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 2.75% and a debt-to-equity ratio of 0.33.
Aarey Drugs & Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Aarey Drugs & Pharmaceuticals Limited share price chart: 16.97% return over the past month. 52-week high ₹101.29, 52-week low ₹50.31.
Aarey Drugs & Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹101.00 | ₹101.00 | ₹94.15 | ₹99.94 | 4.83L (Cr) | |
| ₹98.71 | ₹100.45 | ₹96.10 | ₹98.82 | 2.13L (Cr) | |
| ₹95.71 | ₹100.30 | ₹94.92 | ₹98.89 | 3.70L (Cr) | |
| ₹101.29 | ₹101.29 | ₹94.99 | ₹95.71 | 98.93K (Cr) | |
| ₹99.80 | ₹100.40 | ₹98.00 | ₹99.98 | 2.30L (Cr) | |
| ₹98.47 | ₹99.20 | ₹94.21 | ₹98.03 | 1.43L (Cr) | |
| ₹94.10 | ₹98.50 | ₹94.10 | ₹97.31 | 2.18L (Cr) | |
| ₹96.00 | ₹96.99 | ₹93.55 | ₹95.79 | 1.09L (Cr) | |
| ₹95.00 | ₹95.00 | ₹91.91 | ₹94.44 | 1.46L (Cr) | |
| ₹92.50 | ₹94.00 | ₹91.00 | ₹91.72 | 1.46L (Cr) |
Aarey Drugs & Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹89.67 | ₹101.29 | ₹86.41 | ₹99.94 | +11.45% | |
| ₹80.47 | ₹91.00 | ₹74.60 | ₹88.21 | +9.62% | |
| ₹88.36 | ₹88.37 | ₹73.41 | ₹77.86 | -11.88% | |
| ₹77.99 | ₹92.89 | ₹74.31 | ₹90.16 | +15.60% | |
| ₹90.99 | ₹92.50 | ₹76.30 | ₹77.99 | -14.29% | |
| ₹52.99 | ₹96.00 | ₹52.28 | ₹91.08 | +71.88% | |
| ₹74.94 | ₹75.00 | ₹50.31 | ₹50.75 | -32.28% | |
| ₹64.22 | ₹86.37 | ₹61.08 | ₹76.73 | +19.48% | |
| ₹68.87 | ₹73.00 | ₹60.54 | ₹67.60 | -1.84% | |
| ₹87.40 | ₹87.40 | ₹62.50 | ₹67.67 | -22.57% | |
| ₹96.25 | ₹100.00 | ₹83.78 | ₹87.69 | -8.89% | |
| ₹83.90 | ₹94.97 | ₹79.71 | ₹94.97 | +13.19% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarey Drugs & Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarey Drugs & Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AAREYDRUGS across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Healthy Liquidity Position (Current Ratio: 2.20)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
12 factors identified
Below-Average Return on Equity (2.75%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.10%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.04%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 54.61x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-25.36%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-56.34%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-12.84% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-9.42% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.08x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-5.57 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 5.52%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Aarey Drugs & Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarey Drugs & Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarey Drugs & Pharmaceuticals LimitedAarey Drugs & P...Selected✓ AAREYDRUGS • 524412 | 26/100 | ₹99.94₹100 | ₹284.37₹284.37 | 54.61Average 54.6 Average | 2.75%Poor 2.75% Poor | 7.10%Poor 7.10% Poor | 0.33Excellent 0.3 Excellent | -9.42%Poor -9.42% Poor | 6.27%Good 6.27% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Aarey Drugs & Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for AAREYDRUGS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.43 | ₹67.67 | 47.3x |
| FY 2024 | ₹1.84 | ₹57.10 | 31x |
| FY 2023 | ₹1.49 | ₹50.55 | 33.9x |
| FY 2022 | ₹2.72 | ₹38.65 | 14.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarey Drugs & Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for AAREYDRUGS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-56.34%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-25.36%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.27%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-9.42%
Compounded annual net profit growth over 5 years
Aarey Drugs & Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AAREYDRUGS — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Aarey Drugs & Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Aarey Drugs & Pharmaceuticals Limited
About AAREYDRUGS (Aarey Drugs & Pharmaceuticals Limited)
Aarey Drugs & Pharmaceuticals Ltd is a dynamic player in the pharmaceutical landscape, dedicated to the meticulous crafting of vital chemical components. The company specializes in... the production of high-quality active pharmaceutical ingredients (APIs), catering to a diverse range of therapeutic needs. Beyond APIs, Aarey Drugs distinguishes itself through its expertise in manufacturing sophisticated pharmaceutical intermediates. These carefully synthesized compounds serve as crucial building blocks, enabling the efficient creation of complex drug formulations. A commitment to precision and purity permeates every stage of the manufacturing process, ensuring that the final products meet the stringent demands of the healthcare industry and contribute to improved patient outcomes. Aarey Drugs's product portfolio showcases a balance between established pharmaceutical staples and innovative specialty chemicals. The company offers a selection of essential intermediates, including components used in synthesizing various medications and treatments. These intermediates, produced with rigorous quality control measures, empower pharmaceutical manufacturers to streamline their own production processes. Furthermore, Aarey Drugs is a reliable source for critical APIs, with a focus on producing ingredients that address widespread health concerns. By combining both intermediate and API production, the company positions itself as a comprehensive supplier to the pharmaceutical sector, capable of meeting diverse requirements and supporting the development of a wide array of medications. Supplementing its core manufacturing activities, Aarey Drugs also engages in the responsible trading of essential chemicals and solvents. This division acts as a vital resource for pharmaceutical and chemical companies seeking reliable access to quality materials. A commitment to ethical sourcing and responsible distribution practices underpins this aspect of the company's operations. By maintaining strong relationships with suppliers and adhering to stringent safety standards, Aarey Drugs facilitates the seamless flow of necessary components throughout the industry. This multifaceted approach, encompassing manufacturing and responsible trading, reinforces Aarey Drugs' commitment to supporting the entire pharmaceutical ecosystem.
Company Details
Key Leadership
AAREYDRUGS Share Price: Frequently Asked Questions
What is the current share price of Aarey Drugs & Pharmaceuticals Limited?
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) trades at ₹99.94 on NSE and BSE. Market cap ₹284.37 (Cr). Educational data only.
What is the P/E ratio of Aarey Drugs & Pharmaceuticals Limited?
Aarey Drugs & Pharmaceuticals Limited has a P/E of 54.61x vs industry average 34.89x.
What is the Bull Run score for Aarey Drugs & Pharmaceuticals Limited?
Aarey Drugs & Pharmaceuticals Limited has a Bull Run score of 26/100 based on 25+ financial parameters.
Does Aarey Drugs & Pharmaceuticals Limited pay dividends?
Aarey Drugs & Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Aarey Drugs & Pharmaceuticals Limited?
Aarey Drugs & Pharmaceuticals Limited has ROE of 2.75%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarey Drugs & Pharmaceuticals Limited?
Aarey Drugs & Pharmaceuticals Limited has debt-to-equity of 0.33.
Is Aarey Drugs & Pharmaceuticals Limited a good investment?
Bull Run gives Aarey Drugs & Pharmaceuticals Limited a score of 26/100. This is not investment advice — consult a SEBI-registered advisor.